Biogen (BIIB): Director received 1,505 shares
William A Hawkins, Director at Biogen, reported a grant / award of 1,505 shares.
- 1,505
- Shares
- Traded
- Jun 9, 2026
- Filed
- Jun 11, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 27, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
- Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 8.7%
- May 11, 2026Congress · 1 personMembers of Congress: 2 purchases
- May 12, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
- May 14, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“Pursuant to the Merger Agreement, on April 14, 2026, Purchaser commenced a tender offer (the “Offer”) to acquire any and all of the issued and outstanding Shares, in exchange for (i) $41.00 per Share, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the “Cash Amount”), plus (ii) one contractual, non-transferable contingent value right per Share (each, a “CVR”)…”
- Jun 2, 2026CongressDisclosed sale of BIIB — reported range $15,001 - $50,000
- Jun 5, 20265% stakeFMR LLC reported a passive stake (13G) of 11.3%
- Jun 5, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
What came next
- Jul 1, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 23, 2026Government · Federal Register noticeAdvisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment
- Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 3, 2026InsiderDirector sold ~$121K of BIIB shares in the open market
- Aug 4, 2026InsiderDirector sold ~$119K of BIIB shares in the open market
- Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 12.4%
- Aug 18, 2026CongressDisclosed sale of BIIB — reported range $1,001 - $15,000
- Sep 17, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
- Sep 24, 2026CongressDisclosed partial sale of BIIB — reported range $1,001 - $15,000
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Biogen
For Biogen, OQRO holds 2 Congress trade reports dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BIIB page.
How this filing works
Explore the data
Common questions
Which Biogen (BIIB) insider traded, and how much?
William A Hawkins, Director at Biogen, reported a grant / award of 1,505 shares. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Jun 9, 2026. Filed: Jun 11, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Biogen recently?
For Biogen, OQRO holds 2 Congress trade reports dated in the last 90 days. They are listed on the BIIB page.
Does this mean BIIB stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Biogen
- House Clerk periodic transaction reportOct 7, 2026
- House Clerk periodic transaction reportSep 1, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its BIIB page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
